DDInter1220 DDInter1628
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia, although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Milnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is regulated by {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) regulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) resembles {v} (Compound) Meperidine
Meperidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Levomilnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) regulates {v} (Gene) ARID4B
ARID4B {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) resembles {v} (Compound) Diethylpropion
Diethylpropion {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Milnacipran {u} (Compound) resembles {v} (Compound) Levomilnacipran
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Milnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Ruxolitinib (Compound)
Milnacipran (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Milnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is regulated by JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levomilnacipran (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Milnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) regulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Milnacipran (Compound) resembles Meperidine (Compound) and Meperidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levomilnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Ruxolitinib (Compound)
Milnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) regulates ARID4B (Gene) and ARID4B (Gene) is upregulated by Ruxolitinib (Compound)
Milnacipran (Compound) resembles Diethylpropion (Compound) and Diethylpropion (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ruxolitinib (Compound)
Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levomilnacipran (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)